The breast cancer susceptibility protein, BRCA2, preserves chromosomal stability through roles in the repair of DNA double-strand breaks, and possibly, cell division. Post-translational modifications that may coordinate these functions remain poorly characterized. Here, we report that BRCA2 is a substrate for the mitotic Polo-like kinase, Plk1. BRCA2 undergoes phosphorylation in cells synchronously passing through the G2/M phases of cell cycle, when Plk1 expression and activity are maximal. Depletion of Plk1 by RNA interference suppresses BRCA2 modification. BRCA2 and Plk1 interact with one another in cell lysates, through a conserved region in BRCA2, which spans the eight BRC repeat motifs essential for its function in DNA repair. Within this region, residues positioned between BRC repeats -but not the repeat motifs themselves -are phosphorylated by Plk1. Interestingly, Plk1-mediated modification of BRCA2 during the G2/M phases is inhibited by treatment with the radiomimetic agent, adriamycin. Thus, our findings define a regulatory circuit for BRCA2 phosphorylation by Plk1 that is responsive to DNA damage as well as mitotic progression.
Introduction
Mutations in the breast cancer susceptibility gene, BRCA2, cause breast, ovarian and other cancers. BRCA2-deficient cells exhibit marked instability in chromosome structure during their division, which is exacerbated after DNA damage, leading to the accumulation of gross chromosomal rearrangements such as translocations and end-to-end fusions (Patel et al., 1998; Tutt et al., 1999; Yu et al., 2000) . The chromosomal instability that follows BRCA2 inactivation is expected to accelerate the rate of mutation, providing a plausible explanation for cancer predisposition in this setting (Bertwistle and Ashworth, 1998; Venkitaraman, 2002) .
One biological function of BRCA2 is to regulate the oligomerization of the DNA recombination enzyme RAD51 (Davies et al., 2001; Pellegrini et al., 2002) , which assembles on DNA substrates into a nucleoprotein filament that is essential for DNA repair by homologous recombination (Sung, 1994; Baumann et al., 1996) . BRCA2 binds to RAD51 through a conserved B30 residue motif, the BRC repeat, which recurs eight times in the human protein (Bork et al., 1996; Wong et al., 1997) . BRC repeats structurally mimic the interface between successive RAD51 subunits, consistent with possible roles for BRCA2 in promoting filament assembly or in removing RAD51 from assembled filaments (Pellegrini et al., 2002; Venkitaraman, 2002) .
BRCA2-deficient cells exhibit abnormalities in progression through cell cycle (Connor et al., 1997; Suzuki et al., 1997; Patel et al., 1998) , and BRCA2 has been reported to colocalize with a DNA binding protein, BRAF35, to condensing chromosomes at early stages in mitosis (Marmorstein et al., 2001) . This has engendered the proposal that BRCA2 may have additional roles in cell division. It remains unclear, however, to what extent these observations represent functions distinct fromrather than subservient to -the established role of BRCA2 in homologous recombination.
An attractive -but relatively uncharacterizedpossibility is that post-translational modifications of BRCA2, such as phosphorylation, coordinate its biological functions following DNA damage, or during cell cycle. N-terminal phosphorylation of BRCA2 has been reported (Milner et al., 2000) , but how this modification comes about, or how it is relevant to BRCA2 function, are unknown.
Here, we report the results of experiments designed to address this issue. We show that BRCA2 undergoes phosphorylation during the G2/M phases of cell cycle, and identify an enzyme -the Polo-like kinase Plk1 -that can carry out this modification. Plk1-dependent phosphorylation of BRCA2 is enhanced during mitotic progression, or inhibited by DNA damage, suggesting that it serves to coordinate biological processes in which BRCA2 participates.
Results

Mitotic phosphorylation of BRCA2
HeLa cells were synchronized at the G1/S boundary by double thymidine block ( Figure 1a , 0 h time point), and released into S phase (4 h) in the presence of nocodazole to cause accumulation in the G2/M phases of cell cycle 13 h after release. Transit through G2/M is accompanied by a small but consistent retardation in the mobility of BRCA2 protein detected by Western blotting in wholecell extracts resolved by 3-8% gradient SDS-PAGE (Figure 1b) , suggesting that BRCA2 undergoes posttranslational modification during mitosis.
To analyse this phenomenon further, we divided BRCA2 into nine overlapping fragments and expressed them in bacteria as recombinant proteins fused to an Nterminal glutathione S-transferase (GST) tag (Figure 1c) . The GST-BRCA2 fragments were incubated in the presence of [g-32 P]ATP with extracts prepared from synchronized HeLa cells at the G1/S boundary (0 h time point in Figure 1a ) or during G2/M (13 h, in Figure 1a) , and their phosphorylation was examined by autoradiography after SDS-PAGE (Figure 1d ). Fragments B2-7 and B2-8 were not reproducibly phosphorylated. B2-2 was phosphorylated by G1/S as well as G2/M extracts. Strikingly, fragments B2-1, B2-3, B2-4, B2-5, B2-6 and 
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In vitro interaction between Plk1 and BRCA2
The Polo-like kinase Plk1 is a key regulator of mitotic progression (reviewed in Glover et al., 1998; Nigg, 1998; Weitzer and Uhlmann, 2002) . Among other roles, it works with cyclin-dependent kinases (CDKs) to control entry into mitosis through the phosphorylation of Cdc25C (Abrieu et al., 1998; Qian et al., 1999 Qian et al., , 2001 Roshak et al., 2000; Toyoshima-Morimoto et al., 2002) , promotes loss of cohesion between chromosome arms during mitotic prophase (Losada et al., 2002; Sumara et al., 2002) , and assists the metaphase-anaphase transition by regulating the proteolytic cleavage of cohesin (Alexandru et al., 2001 ). Plk1 activity is responsive to DNA damage, suggestive of functions in coordinating DNA damage responses with mitotic progression (Smits et al., 2000; van Vugt et al., 2001) . Moreover, the maximal activity and expression of Plk1 coincide with the G2/M cell cycle phases in which we detect BRCA2 modification (Hamanaka et al., 1995; Lee et al., 1995; Uchiumi et al., 1997) . We therefore examined the possibility that Plk1 was responsible for BRCA2 phosphorylation. First, we tested if recombinant GST-BRCA2 fragments could bind to Plk1 in extracts prepared from asynchronous HeLa cells. We find (Figure 2a ) that human Plk1 specifically interacts with B2-3, B2-4 and B2-5 fragments -which are also among the regions most heavily modified during progression through mitosis ( Figure 1d ) -suggesting that the kinase could be targeted to BRCA2 through a protein-protein interaction. Consistent with this idea, BRCA2 can be coimmunoprecipitated with transiently overexpressed FLAG epitope-tagged Plk1 (Figure 2b ). However, we cannot demonstrate the interaction without exogenous Plk1 expression, which may reflect the transient nature or weak affinity of this physical association in vivo. Indeed, a stable or strong association need not occur between an enzyme and its substrate, and so our findings remain suggestive rather than definitive.
Plk1 phosphorylates the BRC repeat region but not the repeats themselves
To test if Plk1 phosphorylates BRCA2, we performed an in vitro kinase assay with Plk1 immunoprecipitated from mitotic HeLa extracts, using recombinant GST-BRCA2 fragments as the kinase substrates, in the presence of [g-32 P]ATP. The 32 P label was readily transferred to the fragments B2-3, B2-4 and B2-5 (Figure 3a) , the very same fragments that we have shown to bind Plk1 (Figure 2a ). In addition, B2-1 was also modified with 32 P, and underwent a marked retardation in gel mobility.
The B2-3, B2-4 and B2-5 fragments, to which Plk1 binds and that it phosphorylates, encompass the eight BRC repeat motifs in human BRCA2 (Bork et al., 1996; Wong et al., 1997) . These B30 residue motifs bind directly to RAD51 and regulate its oligomerization state during reactions for the repair of DNA through homologous recombination (Davies et al., 2001; Pellegrini et al., 2002) ; they are essential for the function of BRCA2 in DNA repair (Chen et al., 1998a) . We therefore dissected in further detail the areas modified by Plk1 in the region of BRCA2 encoding the BRC repeats. The region was further subdivided into 17 fragments (Figure 3b ), each of which was individually expressed as a GST fusion protein, and tested for in vitro phosphorylation by immunoprecipitated Plk1 kinase in the presence of [g-32 P]ATP (Figure 3b ). We find that the B1M1, B3M, B3C, BRC34A and BRC6 fragments can be labelled with 32 P. Interestingly, none of the labelled fragments encode the core BRC repeat motifs (Bork et al., 1996; Pellegrini et al., 2002) . Thus, within the BRCA2 fragments, Plk1 does not phosphorylate the BRC repeats themselves, but instead targets residues between these B30 amino-acid motifs.
Depletion of Plk1 suppresses G2/M phosphorylation of BRCA2
Next, we tested if Plk1 was responsible for BRCA2 phosphorylation during G2/M using a new technique of RNA interference (RNAi) to inhibit its expression in synchronized HeLa cells. Cells were first synchronized at the G1/S boundary as before, exposed to the interfering RNA oligonucleotides, and then released synchronously into S phase for further analysis. This technique permits us to analyse perturbations caused by Plk1 depletion during a single, synchronous passage through cell cycle. Plk1 protein is depleted from HeLa cells treated in this way from 7 to 13 h (although some residual Plk1 expression is apparent 13 h after RNAi treatment) following release into S phase ( Figure 4a ).
As noted in Figure 1b , post-translational modification of BRCA2 protein during G2/M at 13 h following release from synchronization is marked by a small alteration in its mobility after SDS-PAGE. The mobility shift is moderately suppressed by Plk1 depletion (Figure 4a ), suggesting that Plk1 is responsible for some, but not all, phosphorylation of BRCA2 during the G2/M phases. To further verify this, we tested the ability of HeLa extracts to label GST-BRCA2 fragments with [g-32 P]ATP, before and after Plk1 depletion by RNAi.
As expected, phosphorylation of the BRC34A fragment is increased in extracts prepared from cells arrested in G2/M by treatment with nocodazole ( Figure 4b , compare lanes 1 and 2). The enhanced phosphorylation of this fragment in G2/M extracts can be moderately suppressed by depletion of Plk1 by RNAi (Figure 4b , compare lanes 2 and 3), consistent with the notion that this modification is at least in part the result of Plk1 activity.
BRCA2 phosphorylation by Plk1 is inhibited by DNA damage
While Plk1 expression and activity are enhanced as cells progress through mitosis, kinase activity (but not expression) is suppressed after exposure to DNAdamaging agents (Smits et al., 2000) . These changes are reflected in the Plk1-dependent phosphorylation of the substrate a-casein in synchronized cells at 8-13 h after release into S phase (Figure 5a ). Maximal Plk1 activity at 11 and 13 h after release coincides with 
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MiYoung Lee et al maximal expression of the kinase (Figure 5b ). Treatment of synchronized cells with the radiomimetic agent, adriamycin, which induces double-strand DNA breakage, greatly diminishes Plk1 activity in a-casein phosphorylation ( Figure 5a ) but with little effect on expression (Figure 5b ). To determine whether diminished Plk1 activity after DNA damage also causes diminished BRCA2 phosphorylation during progression through G2/M, we examined the mobility of BRCA2 in synchronized cells at 8-13 h after release into S phase in the presence of adriamycin. Indeed, the retardation of BRCA2 mobility observed at 11 and 13 h in untreated control cells is suppressed by treatment with adriamycin ( Figure 5c ). Furthermore, the ability of Plk1 immunoprecipitated from synchronized cell extracts to phosphorylate the BRC34A fragment, maximal during G2/M progression (11/13 h) in untreated cells, is suppressed after adriamycin treatment (Figure 5d ). Thus, when taken together, our results show that DNA damage suppresses Plk1-dependent phosphorylation of BRCA2 during mitotic progression.
Interestingly, somewhat less BRCA2 protein is detected in cell extracts from adriamycin-treated cells. Indeed, it has been reported that BRCA2 mRNA and protein levels are downregulated in a p53-dependent manner after treatment of cells with a high dose (5 mM) of adriamycin for 1 h, or a low dose (0.7 mM) for 24 h (Wu et al., 2003) . However, these experimental conditions are significantly different from those we have used here, in that we treated cells with a low dose (0.5 mM) of adriamycin for 1 h. This leaves open the possibility that the decrease in BRCA2 abundance, which we observe may be the result of mechanisms other than downregulated expression.
Discussion
Collectively, our findings provide several lines of evidence that the Plk1 kinase phosphorylates BRCA2 in a cell-cycle-dependent manner during mitotic progression. The retardation in the electrophoretic mobility of BRCA2 in cells progressing synchronously through G2/M can be suppressed by depletion of Plk1 using RNAi. Recombinant proteins encoding fragments of BRCA2 can be phosphorylated in vitro by immunoprecipitated Plk1, and this reaction can also be inhibited by Plk1 depletion. Finally, BRCA2 and Plk1 interact physically at least under our in vitro conditions, through a region encoded in the conserved exon 11 of BRCA2 that also undergoes Plk1-mediated phosphorylation.
Plk-1 modifies multiple sites in BRCA2. We show that recombinant proteins encoding the N-terminal 454 residues of BRCA2 (B2-1), and a region spanning residues 885-2115 in conserved exon 11 (B2-3, B2-4, B2-5), all undergo phosphorylation by Plk1. The biological effects of Plk1-dependent modification on BRCA2 may well depend on which of several residues becomes phosphorylated. The identification and analysis of these changes is a significant matter for further work.
Plk1 physically interacts with a region spanning residues 885-2115 in BRCA2, which includes the majority of exon 11 encoded sequences. This region is also the preferred target of phosphorylation during G2/ M. It includes the eight evolutionarily conserved BRC repeat motifs, BRC1-BRC8, which bind to the RAD51 recombinase and regulate its oligomerization. Contrary to our expectation, however, Plk1 phosphorylates residues interleaved between BRC repeats BRC1 and BRC2, BRC2 and BRC3 and BRC5 and BRC6, while sparing the B30 residue core BRC motifs themselves. Whether or not modification of the BRC repeat region by Plk1 affects the interaction between BRCA2 and the RAD51 recombinase remains to be tested, but seems unlikely, given that the core BRC motifs sufficient for RAD51 binding are not themselves affected.
The phosphorylation of BRCA2 by Plk1 is coordinately regulated not only during cell cycle progression, To measure activity, Plk1 was immunoprecipitated from cell extracts prepared at each time point and used to phosphorylate a-casein. In aliquots of the same extracts used for activity assays, expression of Plk1 (b) and BRCA2 (c) was analysed by Western blot. A small increase in BRCA2 abundance is variably observed during G2/M in untreated extracts. (d) Aliquots of the extracts were also used to determine the ability of immunoprecipitated Plk1 to phosphorylate the BRC34A fragment using the IP-kinase assay Phosphorylation of BRCA2 by Plk1 MiYoung Lee et al but also in response to DNA damage. When cells passing synchronously through G2/M are treated with the radiomimetic agent adriamycin, Plk1 activity (Smits et al., 2000) and BRCA2 modification are both suppressed. We propose a model in which this regulatory circuit coordinates distinct functions of BRCA2 (Figure 6) . During S phase, BRCA2's major functional role is believed to be in the repair of DNA double-strand breakage associated with replication (Chen et al., 1998b; Venkitaraman, 2000; Yu et al., 2000) . As cells enter mitosis, however, BRCA2 is observed to localize to condensing chromosomes, and a role in this process has been postulated but not established (Marmorstein et al., 2001) . Thus, one possibility is that Plk1-mediated phosphorylation at the transition from S phase to mitosis alters the spectrum of proteins interacting with BRCA2, in turn 'switching' its functions from DNA repair to mitotic regulation ( Figure 6 ). It is consistent with this idea that induction of DNA damage late in S phase inhibits BRCA2 modification. In our model, this would permit BRCA2 to maintain functions relevant to DNA repair, delaying the eventual 'switch' to its roles during mitosis. The precise mechanisms underlying the changes in BRCA2 function, we posit here remain to be clarified. It seems clear, however, that further studies to identify the proteins that associate with BRCA2 in the phosphorylated versus nonphosphorylated states are warranted.
Our results also raise the possibility that perturbation of BRCA2 regulation could occur in cancer cells that overexpress Plk1. Elevated Plk1 expression has been reported in a wide range of human epithelial malignancies, including colorectal cancer, ovarian cancer and carcinoma of the breast, where it has been linked to invasiveness and poor prognosis (Wolf et al., 1997 (Wolf et al., , 2000 Tokumitsu et al., 1999; Takai et al., 2001a, b; Takahashi et al., 2003) . In this setting, dysregulation of Plk1 expression may, in turn, alter BRCA2 phosphorylation and function, inducing genetic instability. Further studies are in progress to ascertain whether or not this hypothetical mechanism contributes to the pathogenesis of cancers that overexpress Plk1.
Materials and methods
Cell culture
HeLa and 293T cells were grown in Dulbecco's modified Eagle' medium supplemented with 10% foetal bovine serum in the presence of antibiotics. To synchronize HeLa cells by double-thymidine block, cells were treated with 2 mM thymidine overnight, released for 10 h and treated again with thymidine overnight. Cells were released into growth medium containing nocodazole (120 ng/ml) to enrich mitotic cells. Cell cycle profiles were analysed by flow cytometry after staining with propidium iodide (Sigma) as previously described (Patel et al., 1998) . Where noted, HeLa cells were treated with adriamycin (0.5 mM, doxorubicin HCl, Sigma) for 1 h at 7 h after release into S phase.
Plasmids and transfection
GST-BRCA2 fragments were cloned into pGEX-4T3 vector (Amersham Biosciences), expressed in Escherichia coli, and purified on Glutathione-Sepharose 4B beads (Amersham Biosciences). Human Plk1 cDNA was cloned into p3XFLAG-CMV-10 vector (Sigma) and used to transiently transfect 293T cells by the calcium phosphate method (MBS Mammalian Transfection Kit, Stratagene).
Western blot and immunoprecipitation
Whole-cell extracts were made in the NP-40 lysis buffer (50 mM HEPES (pH 7.4), 100 mM NaCl, 0.5% NP-40, 10 mM EDTA, 20 mM b-glycerophosphate, 1 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF, complete protease inhibitor cocktail (Roche)). BRCA2 was resolved by 3-8% gradient Tris-acetate gels (Invitrogen) and detected with anti-BRCA2 monoclonal antibody Ab-1 (Merck Biosciences). Plk1 was detected with an anti-Plk1 monoclonal antibody cocktail (Zymed). For immunoprecipitation, FLAG-Plk1 was transiently expressed in 293T and immunoprecipitated with anti FLAG monoclonal antibody M2 (Sigma). Immunoprecipitates were washed extensively in NP-40 lysis buffer before resolution by SDS-PAGE before Western blotting, or use in phosphorylation assays.
In vitro phosphorylation
For in vitro phosphorylation with cell extracts, cells were lysed in the kinase buffer (50 mM HEPES (pH 7.4), 50 mM NaCl, 10 mM MgCl 2 , 20 mM b-glycerophosphate, 1 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF) plus 0.1% NP-40. GST-BRCA2 fragments on the Glutathione-Sepharose 4B beads were incubated in the kinase buffer with cell extracts, 0.5 mM ATP, and 5 mCi of [g-32 P]ATP for 20 min at 301C, and the beads were washed with the NP-40 lysis buffer. Phosphorylated proteins were eluted by addition of sample buffer and analysed by 10% SDS-PAGE before autoradiography. For the IP-kinase assay, Plk1 was immunoprecipitated from nocodazole-treated (120 ng/ml) HeLa cells with anti-Plk1 rabbit polyclonal antibody (Merck Biosciences) as described above, washed with the kinase buffer, mixed with GST-BRCA2 proteins bound to beads and incubated as described with [g-32 P]ATP. The dephosphorylated form of a-casein Figure 6 Hypothetical model for phosphorylation of BRCA2 by Plk1. Plk1-dependent phosphorylation of BRCA2 is triggered by transit through the G2/M phases of cell cycle, and removed during interphase (arrows). Phosphorylation may alter the spectrum of proteins bound to BRCA2, displacing some proteins bound during S phase (small oval), or promoting the binding of others (star). These changes may help to distinguish functions of BRCA2 in DNA repair during S phase from roles in mitosis during G2/M. DNA damage blocks Plk1-dependent phosphorylation as well as entry into mitosis, maintaining the DNA repair functions of BRCA2
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GST pull-down assay GST-BRCA2 fragments bound to Glutathione-Sepharose beads were incubated with HeLa cell extracts in binding buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 10 mM NaF, complete protease inhibitor cocktail (Roche)) for 20 min at room temperature. The beads were then washed extensively with the binding buffer and analysed by 10% SDS-PAGE before Western blotting.
RNAi Double-stranded short interfering (si) RNA oligonucleotides were synthesized (Xeragon) against a target sequence in human Plk1 (5 0 -CGACTTCGTGTTCGTGGTG-3 0 ) corresponding to the coding regions 369-387 relative to the first nucleotide of the start codon. HeLa cells synchronized at the G1/S boundary by double-thymidine block were transfected with Plk1 siRNA, using 10 ml of a 20 mM stock of RNA per well of a six-well tissue culture plate with 4 ml of Oligofectamine reagent (Invitrogen). G1/S arrested cells were released into S phase in media containing nocodazole as described previously to enrich for mitotic cells. Transfections with siRNAs were carried out in the presence of serum to facilitate subsequent release from the thymidine block. Cells were harvested 7 and 13 h after release for the analysis of BRCA2 and Plk1 protein expression by Western blotting. For in vitro phosphorylation with Plk1-depleted cell extracts, HeLa cells were transfected with Plk1 siRNA in 6-cm dishes in the absence of serum. Cells were treated with nocodazole overnight before harvesting 48 h after transfection for the preparation of cell extracts.
